EPIDAREX CAPITAL – CATALYZING INNOVATION IN HEALTH SCIENCE AND TECHNOLOGY
NEWS
Rezera Announces Positive RESOLVE-2 Phase 2 Clinical Trial Results Demonstrating FavorableSafety and Tolerability Profile for Ruvonoflast in Combination with Semaglutide
Combination of ruvonoflast and semaglutide produced greater reductions in hsCRP versussemaglutide monotherapy Boston, MA, October 7, 2026 – Rezera Inc. (the “Company”), a clinical-stage biotechnology
RougeTx Launches with $58 Million Series A Financing to Advance First-in-Class Treatment for Hereditary Hemorrhagic Telangiectasia
· Epidarex Capital Fund IV participates in Series A alongside BioGeneration Ventures, Angelini Ventures, Kurma Partners, Vesalius Biocapital Partners, ROM-Utrecht Region, p53 Invest and Kerna
Mironid successfully doses initial cohorts in Phase 1 clinical trial investigating the Company’s first-in-class LoAc® small molecule for patients with ADPKD
Glasgow, Scotland, October 1, 2026 – Mironid, a biopharmaceutical company developing small molecule therapeutics for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), a
Rezera Announces Late-Breaking Presentation of RESOLVE-1 Clinical Data at the American Heart Association (AHA) Scientific Sessions 2026
Boston, MA, September 23, 2026 – Rezera Inc. (the “Company”), a clinical-stage biotechnology company developing a portfolio of internally-invented and wholly-owned oral inhibitors of NLRP3
Rezera Announces Ruvonoflast Met its Primary Inflammation Endpoint and Demonstrated Favorable Safety Profile in RESOLVE-1 Phase 2 Clinical Trial
Rezera has aligned with regulators on trial design of Phase 3 study of ruvonoflast in peripheral artery disease (PAD), expected to initiate in 1H of
NodThera Inc. Changes Name to Rezera Inc. and Announces Ruvonoflast Phase 3 Development Program
Rezera plans to advance ruvonoflast into a Phase 3 clinical trial in peripheral artery disease (PAD) in H1 of 2027 Boston, MA, September 9, 2026
NodThera to Participate in Cantor Global Healthcare Conference
Boston, MA, September 2, 2026 – NodThera, a leading clinical-stage company developing a portfolio of potentially best-in-class brain-penetrant oral NLRP3 inhibitors to address inflammatory drivers
EPIDAREX ANNOUNCES LEADERSHIP APPOINTMENTS
With the launch of our latest fund, Epidarex Capital IV, LP, we are pleased to announce several promotions. As we continue to grow and deepen